Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-24T13:23:07.609Z Has data issue: false hasContentIssue false

45 - National Institute on Aging’s Alzheimer’s Disease Translational Research Program: Diversifying the Drug-Development Pipeline for the Treatment and Prevention of Alzheimer’s Disease and Related Dementias

from Section 7 - Funding and Financing Alzheimer’s Disease Drug Development

Published online by Cambridge University Press:  03 March 2022

By
Laurie Ryan ,
Suzana Petanceska  and
Lorenzo Refolo
Edited by
Jeffrey Cummings ,
Jefferson Kinney  and
Howard Fillit
Jeffrey Cummings
Affiliation:
University of Nevada, Las Vegas
Jefferson Kinney
Affiliation:
University of Nevada, Las Vegas
Howard Fillit
Affiliation:
Alzheimer’s Drug Discovery Foundation
Get access

Summary

The National Institutes of Health (NIH) is the largest funder of Alzheimer’s disease and related demententias (AD/ADRD) research in the world. The National Institute on Aging (NIA), part of the NIH, leads the federal effort on AD/ADRD research. Since 2005 the NIA has been developing a robust translational research program for the treatment and prevention of AD dementia. In 2011, the National Alzheimer’s Project Act became law and ordered the creation of a National Plan to Address Alzheimer’s Disease. The National Plan was first released in 2012 and the first goal of the plan is to find effective ways to treat or prevent dementia by 2025. Since the first the release of the first National Plan in 2012, NIA’s funding for AD/ADRD research has steadily increased, allowing continued expansion and diversification of the drug development portfolio and the development of translational infrastructure programs to accelerate the discovery of effective therapies.

Keywords

Drug DevelopmentClinical DevelopmentOpen ScienceTranslationalInfrastructureClinical TrialsData DrivenPredictive Drug DevelopmentData Sharing
Type
Chapter
Information
Alzheimer's Disease Drug Development
Research and Development Ecosystem
 , pp. 503 - 512
Publisher: Cambridge University Press
Print publication year: 2022

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

National Institutes of Health. NIH professional judgment budget for Alzheimer’s disease and related dementias for fiscal year 2022. Available at: www.nia.nih.gov/sites/default/files/2020-07/bypass-budget-report-FY-2022.pdf (accessed January 18, 2021).Google Scholar
Kelley, AS, McGarry, K, Gorges, R, Skinner, JS. The burden of health care costs for patients with dementia in the last 5 years of life. Ann Intern Med 2015; 163: 729–36.Google Scholar
Refolo, L. From mouse to medicine: improving preclinical research in Alzheimer’s disease. Available at: www.nia.nih.gov/research/blog/2017/02/mouse-medicine-improving-preclinical-research-alzheimers-disease (accessed January 18, 2021).Google Scholar
Petanceska, S, Ryan, L, Silverberg, N, Buckholtzet, N. Commentary on ‘‘A roadmap for the prevention of dementia II. Leon Thal Symposium 2008.’’ Alzheimer’s disease translational research programs at the National Institute on Aging. Alzheimers Dement 2009; 5: 130–2.CrossRefGoogle Scholar
Buckholtz, NS, Ryan, LM, Petanceska, S, Refolo, LM. NIA commentary: translational issues in Alzheimer’s disease drug development. Neuropsychopharmacol Rev 2012; 37: 284–6.CrossRefGoogle ScholarPubMed
Weninger, S, Carrillo, MC, Dunn, B, et al. Collaboration for Alzheimer’s prevention: principles to guide data and sample sharing in preclinical Alzheimer’s disease trials. Alzheimers Dement 2016; 12: 631–2.Google Scholar
Ryan, L, Petanceska, S. Raising the bar on data and biosample sharing from AD/ADRD clinical trials. Available at: www.nia.nih.gov/research/blog/2020/12/raising-bar-data-and-biosample-sharing-ad-adrd-clinical-trials (accessed January 18, 2021).Google Scholar
Sperling, RA, Jack, CR Jr., Aisen, PS. Testing the right target and right drug at the right stage. Sci Transl Med 2011; 3: 111cm33.CrossRefGoogle ScholarPubMed
Petanceska, S, Refolo, L. Open science delivers a wealth of AD/ADRD research data to a portal near you. Available at: www.nia.nih.gov/research/blog/2020/11/open-science-delivers-wealth-ad-adrd-research-data-portal-near-you (accessed January 18, 2021).Google Scholar
Greenwood, AK, Montgomery, KS, Kaueret, N, et al. The AD knowledge portal: a repository for multi-omic data on Alzheimer’s disease and aging. Curr Protoc Hum Genet 2020; 108: e105.CrossRefGoogle Scholar
Oblak, AL, Forner, S, Territo, PR, et al. Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease: MODEL-AD. Alzheimers Dement 2020; 6: e12110.CrossRefGoogle ScholarPubMed
Sukoff Rizzo, SJ, Masters, A, Onoset, KD, et al. Improving preclinical to clinical translation in Alzheimer’s disease research. Alzheimers Dement 2020; 6: e12038.Google Scholar
Weiner, MW, Veitch, DP, Aisen, PS, et al. Recent publications from the Alzheimer’s Disease Neuroimaging Initiative: reviewing progress toward improved AD clinical trials. Alzheimers Dement 2017; 13: e1–85.Google Scholar
Sperling, RA, Donohue, MC, Raman, R, et al. Association of factors with elevated amyloid burden in clinically normal older individuals. JAMA Neurol 2020; 77: 735–45.CrossRefGoogle ScholarPubMed
Bernard, M. Announcing NIA’s new crop of research concepts! Available at: www.nia.nih.gov/research/blog/2020/09/announcing-nias-new-crop-research-concepts (accessed January 18, 2021).Google Scholar
Institute of Medicine. Sharing Clinical Trial Data: Maximizing Benefits, Minimizing Risk. Washington, DC: The National Academies Press; 2015.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×